Gordon Saul

Bio

Gordon Saul joined InterWest's life sciences team in 2003 and currently holds operating roles in two InterWest portfolio companies: founder, chief business officer and chief financial officer of Carbylan BioSurgery; and founder, president and chief executive officer of RadioRx. Earlier at InterWest, Saul was on the founding team of AlgoRx Pharmaceuticals (ANSV), holding both chief financial officer and chief business officer roles. He led strategic partnering efforts for the following InterWest portfolio companies: AkaRx and Kai. He is also actively involved in InterWest's investment in ODTx. Saul has almost 20 years startup and business development experience in the pharmaceutical and medical device areas. Prior to joining InterWest, he was a co-founder, board member and senior vice president of business development and marketing for PowderJect Pharmaceuticals, a publicly traded drug delivery company acquired by Chiron Corporation in 2003. Prior to PowderJect, he held business development roles at ALZA Corporation and Advanced Cardiovascular Systems, a division of Guidant Corp. He has also worked in Japan in the financial services industry and in management consulting for The Boston Consulting Group. Saul received an A.B. in engineering sciences from Dartmouth College and an M.B.A. from Stanford University.